HitGen Ltd, a biotech company located in China, is specialized in drug discovery and development based on its DNA Encoded Library technology platform. Our DNA encoded libraries currently include hundreds of billions of small molecules with novel, diverse and drug-like structures, which can be accessed by partners to identify novel hit and lead compounds against a variety of therapeutic target classes.
Over 50 collaborations have been signed since 2016 including several top 10 Pharmas.
Leveraging the platform, internal innovative drug research & development pipeline focusing on oncology, inflammation/respiratory, CV, metabolism and ophthalmology has been developed, and some projects are also ready for partnering and out-licensing.
Our DNA encoded libraries currently include hundreds of billions of small molecules with novel, diverse and drug-like structures, which can be accessed by partners to identify novel hit and lead compounds against a variety of therapeutic target classes. General screening process: Incubate the active immobilized target protein and DNA encoded library for some time; during the time, compounds with strong affinity will bind to the protein while non-binders / weak-binders will be eluted. Denature the protein with heat and elute the selected binders. Elucidate the structure of binders through PCR amplification / DNA sequencing. Re-synthesize off-DNA for confirmation of activity. Optimize chemical structure to generate lead compounds.
HitGen offer service for customized DNA Encoded Library synthesis. DNA-encoded libraries are hybrid-type libraries that bring together beneficial aspects from conventional combinatorial libraries and display technologies, such as phage display. The practice of “Split & Pool” strategy enables production of huge collections of molecules. Furthermore, every compound in the libraries is encoded with a given sequence of DNA on molecular level. By using diverse actives as scaffolds, HitGen can achieve the chemical diversity and novelty of DELs.
Integrated drug discovery project. Service from target screening using DNA encoded libraries until IND Filing.
Leveraging the DNA Encoded Library platform, we also have several internal R&D programs which are available for licensing discussion: HDAC I/IIb, Trk, STING, IL-17A, HDAC6 and ROCK2.
Hits identification by screening changeable targets against our DNA Encoded Library which include hundreds of billions of novel small molecules.
HitGen Ltd. has not received any reviews.
HitGen Ltd. has not received any endorsements.